Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

Area of Science:

• Oncology
• Gene Therapy
• Immunology

Background:

• RTVP-1 (Radiation-induced Tumor-derived Protein 1) is a novel p53 target gene.
• RTVP-1 exhibits cytotoxic and immunostimulatory activities with potential for cancer gene therapy.

Purpose of the Study:

• To evaluate the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model for prostate cancer.
• To assess the efficacy of an adenoviral vector expressing RTVP-1 (AdRTVP-1) in preventing tumor recurrence and metastasis.

Main Methods:

• A mouse prostate cancer cell line (178-2 BMA) was transduced with AdRTVP-1 or a control adenoviral vector (Adbetagal).
• Irradiated, gene-modified cells were used as a vaccine in syngeneic mice, followed by challenge with orthotopic tumor cells.
• Tumor growth, metastasis, survival rates, and immune cell activity (NK and CTL) were monitored.

Main Results:

• RTVP-1-cell vaccination significantly reduced the incidence of tumor development (fewer than 60% vs. 100% in controls).
• Primary tumor weight, lung metastasis, and mortality were significantly decreased in the RTVP-1 vaccinated group.
• Vaccination with AdRTVP-1 led to significantly increased Natural Killer (NK) and Cytotoxic T Lymphocyte (CTL) activities.

Conclusions:

• RTVP-1 gene-modified cell-based vaccines demonstrate significant therapeutic efficacy against prostate cancer in a preclinical model.
• These findings suggest RTVP-1 gene therapy holds potential for preventing recurrent prostate cancer.
• The immunostimulatory properties of RTVP-1 contribute to its anti-tumor effects, highlighting its value in cancer vaccine development.